Pathologic complete response (pCR) to neoadjuvant treatment with or without atezolizumab in triple-negative, early high-risk and locally advanced breast cancer: NeoTRIP Michelangelo randomized study-Reference-Cited by-同舟云学术

Pathologic complete response (pCR) to neoadjuvant treatment with or without atezolizumab in triple-negative, early high-risk and locally advanced breast cancer: NeoTRIP Michelangelo randomized study

Published:2022-05 Issue:5 Volume:33 Page:534-543
ISSN:0923-7534
Container-title:Annals of Oncology
language:en
Short-container-title:Annals of Oncology

Author:

Gianni L.,Huang C.S.,Egle D.,Bermejo B.,Zamagni C.,Thill M.,Anton A.,Zambelli S.,Bianchini G.,Russo S.,Ciruelos E.M.,Greil R.,Semiglazov V.,Colleoni M.,Kelly C.,Mariani G.,Del Mastro L.,Maffeis I.,Valagussa P.,Viale G.

Publisher

Elsevier BV

Subject

Oncology,Hematology

Reference21 articles.

1. Gene pathways associated with prognosis and chemotherapy sensitivity in molecular subtypes of breast cancer;Iwamoto;J Natl Cancer Inst,2011

2. Tumor-associated lymphocytes as an independent predictor of response to neoadjuvant chemotherapy in breast cancer;Denkert;J Clin Oncol,2010

3. Subtype-specific metagene-based prediction of outcome after neoadjuvant and adjuvant treatment in breast cancer;Callari;Clin Cancer Res,2016

4. Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients;Herbst;Nature,2014

5. Platinum-based chemotherapy in metastatic breast cancer: current status;Decatris;Cancer Treat Rev,2004

Cited by 158 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Immunotherapy for breast cancer: New strategies to enhance the patient selection and overcome therapeutic resistance;Principles of Immunotherapy Breast and Gastrointestinal Cancers;2025

2. Evolving immunotherapeutic solutions for triple-negative breast carcinoma;Cancer Treatment Reviews;2024-11

3. Is neoadjuvant treatment indicated in triple negative cT1N0 breast cancer?;Revista de Senología y Patología Mamaria;2024-10

4. Synergizing Immunotherapy and Antibody–Drug Conjugates: New Horizons in Breast Cancer Therapy;Pharmaceutics;2024-08-29

5. Neoadjuvant Immune Checkpoint Inhibitors Plus Chemotherapy in Early Breast Cancer;JAMA Oncology;2024-08-29